Loading...
Loading...
OCS| Name | Value |
|---|---|
| Revenues | 239.5K |
| Cost of Revenue | 6,173.0K |
| Gross Profit | -5,933.5K |
| Operating Expense | 9,961.0K |
| Operating I/L | -44,824.0K |
| Other Income/Expense | -1,067.0K |
| Interest Income | 33.0K |
| Pretax | -45,891.0K |
| Income Tax Expense | 124.0K |
| Net Income/Loss | -46,015.0K |
Oculis Holding AG is a clinical-stage biopharmaceutical company specializing in developing novel topical treatments for ophthalmic diseases. Their lead candidate, OCS-01, is a topical dexamethasone formulation in Phase 3 clinical trials for diabetic macular edema. OCS-02, a topical biologic candidate, is in Phase 2b clinical trials for dry eye disease, and OCS-05 is a neuroprotective agent for various neuro-ophthalmic disorders. The company generates revenue through the development and potential commercialization of these innovative ophthalmic treatments.
